search
Back to results

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

Primary Purpose

CMT

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Engensis (VM202)
Sponsored by
Helixmith Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for CMT

Eligibility Criteria

19 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males or females ≥ 19 years of age and ≤ 65 years of age
  2. Patients with confirmed diagnosis of CMT1A by genetic testing
  3. Patients with mild to moderate severity assessed by Charcot Marie Tooth Neuropathy Score version 2 (CMTNS v2) with a score > 2 and ≤ 20
  4. Individuals with lower limb muscle weakness with minimum dorsiflexion or more
  5. Individuals who voluntarily consented to participate in this study and signed the IRB approved informed consent form after listening to a description on the characteristics of this clinical study prior to all screening tests
  6. Individuals who can comply with the requirements in the clinical study
  7. In case of females of child bearing potential, those who test negative in a urine or serum pregnancy test at screening
  8. Individuals who practice medically approved contraceptive methods throughout the clinical study

Exclusion Criteria:

  1. Patients with significant respiratory, circulatory, renal, gastrointestinal, hepatic, endocrine, hematologic, psychiatric disorders or other severe diseases, or alcohol or drug addiction who may develop safety issues or cause confusion in the interpretation of the clinical study results as determined by the principal investigator
  2. Patients with other neuromuscular diseases or neuropathy-inducing factors: Patients with chronic alcohol addiction, undergoing anticancer chemotherapy, or taking neurotoxic drugs
  3. Patients diagnosed with diabetes
  4. Patients diagnosed with inflammatory bowel disease
  5. Patients with a history of stroke or cerebral ischemic attack within 12 months prior to the screening date
  6. Patients with a history of coronary artery disease, such as myocardial infarction and unstable angina pectoris, within 12 months prior to the screening date
  7. Morbidly obese patients with body mass index (BMI) ≥ 37
  8. Patients who underwent orthopedic surgery (corrective surgery for bone and ligament, artificial joint implantation, osteosynthesis, osteotomy, arthroscopic surgery) in the lower limbs within 6 months prior to the screening date
  9. Patients who may be affected by the muscle strength measurement test due to ankle contracture or surgery
  10. Patients with uncontrolled hypertension (if systolic blood pressure is ≥ 160 mmHg or diastolic blood pressure is ≥ 100 mmHg at screening)
  11. Patients or patient's immediate family members (parents, siblings, offspring) with a history of malignant tumors within the last 5 years prior to the screening date, excluding basal cell carcinoma or squamous cell carcinoma that occurs on the skin (if it is determined that there is no possibility of relapse after resection), or with a family history of familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC)
  12. Patients who have not completed a national cancer screening program applicable to their sex and age (if it cannot be confirmed that the relevant test was received at a national cancer screening center or a recognized screening center)

    However, if it is confirmed that the relevant test was received at a national cancer screening center or a recognized screening center during the screening period, and that the results were within normal range, the patients may participate in the clinical study.

    Common to males and females: If a patient is ≥ 50 years of age, the results of a colonoscopy within 5 years prior to the screening must be determined as being within normal range, and if adenomatous polyps are evident, the results of a colonoscopy within 1 year must be determined as being within normal range (inflammatory polyps or hyperplastic polyps are included in the normal range). If a patient is ≥ 40 years of age, the results of a gastroscopy within 2 years prior to the screening must be within normal range. If a patient is ≥ 54 years of age and has a 30 pack-year history of smoking or more, the results of a low-dose chest CT within 2 years prior to the screening must be within normal range. In case of liver cancer, carriers of hepatitis B or hepatitis C virus and patients with hepatic cirrhosis fall under the exclusion criteria.

    Females: For females ≥ 40 years of age, normal range findings must be confirmed in a mammogram within 2 years. For females ≥ 20 years of age, normal range findings must be confirmed in a Pap smear within 2 years.

  13. Patients diagnosed with active pulmonary tuberculosis
  14. Patients with HBV or HCV
  15. Patients who test positive in human immunodeficiency virus (HIV) antibody test
  16. Patients in an immunosuppressive state due to treatments such as immunosuppressants, chemotherapy, and radiotherapy
  17. Patients with a history of mental disease within 6 months prior to the screening date, which may interfere with participation in the study
  18. Patients who must take medications, that are known to have significant drug interactions within 14 days after the first administration of the investigational product or deemed unsuitable by the investigator's judgment
  19. Individuals who participated in another clinical study within 6 months before the time of screening
  20. Individuals who have shown significant adverse events such as hypersensitivity reactions to the investigational product
  21. Pregnant or breastfeeding females
  22. Other individuals determined ineligible by the principal investigator to participate in the clinical study due to other reasons including clinical laboratory test results

Sites / Locations

  • Samsung Medical Center, Seoul National University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Engensis (VM202)

Arm Description

56 (ea) 0.25mg (0.5 mL) injections in each of the left and right lower limbs on Days 0, 14, 90, and 104.

Outcomes

Primary Outcome Measures

Safety of intramuscular (IM) injections of Engensis in Participants
Frequency and percentage of treatment-emergent adverse events (TEAEs) and serious adverse events after injections, injection site reactions, vital sign, and clinically significant laboratory values for Engensis.

Secondary Outcome Measures

Evaluation of Severity of disease changes following Engensis injections
As assessed using the CMTNS v2 (Charcot Marie Tooth Neuropathy Score version The scores range from 0-36. The severity of disease shall be classified according to scores as mild (≤10), moderate (11 to 20), and severe (>20).
Evaluation of patient's neurological disability
As assessed using the FDS (functional disability scale). normal is 0 point, and if determined as bedridden, it is evaluated as 8 points.
Evaluation of the activity level of patients with peripheral neuropathy
As assessed using the overall neuropathy limitation scale (ONLS) leg scale. It is scored from 0 to 7. The worst score, 7 points, is defined as restricted to wheelchair, or bed most of the day, unable to make any purposeful movements of the leg.
Evaluation of patient's walking ability
This test measures the time required for a subject to walk 10m through the 10-Meter Walking Test (10MWT) v2.2.
Changes in fatty infiltration level of lower limb muscles
Imaged via MRI.
Evaluation of the presence of a disorder in a neurotransmission pathway.
As assessed using the Nerve Conduction Study (NCS) v2.0
Evaluation of the presence of hepatocyte growth factor in the body.
As assessed using Anti-HGF Ab test

Full Information

First Posted
March 31, 2022
Last Updated
April 28, 2022
Sponsor
Helixmith Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05361031
Brief Title
The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Official Title
Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
September 21, 2020 (Actual)
Primary Completion Date
September 9, 2021 (Actual)
Study Completion Date
September 9, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Helixmith Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
To assess the safety and tolerability of the investigational product (VM202) injected in the weakened lower limb muscles of CMT1A patients
Detailed Description
There are no therapeutic agents for CMT to date. Attempts were made to develop therapeutic agents, but efficacy could not be demonstrated in clinical studies. Most of the attempted developments for therapeutic agents targeted alleviating the symptoms of CMT1A by regulating the expression of PMP22. This study will use Engensis (VM202), which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. HGF has been thought of as an angiogenic factor, but it has been recently identified as serving the role of a neurotrophic factor. Moreover, it has been reported that it can contribute to muscle tissue regeneration by targeting on muscles. Considering the pathologic mechanism of CMT, the biological activity of HGF helps peripheral nerve regeneration, relieves muscle atrophy, and reduces pain, so it is highly likely to show a therapeutic effect for CMT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
CMT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Single center, repeat dose, open label, phase I/IIA clinical study
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Engensis (VM202)
Arm Type
Experimental
Arm Description
56 (ea) 0.25mg (0.5 mL) injections in each of the left and right lower limbs on Days 0, 14, 90, and 104.
Intervention Type
Biological
Intervention Name(s)
Engensis (VM202)
Intervention Description
Intramuscular injections
Primary Outcome Measure Information:
Title
Safety of intramuscular (IM) injections of Engensis in Participants
Description
Frequency and percentage of treatment-emergent adverse events (TEAEs) and serious adverse events after injections, injection site reactions, vital sign, and clinically significant laboratory values for Engensis.
Time Frame
Day 0 visit to the Day 270 visit
Secondary Outcome Measure Information:
Title
Evaluation of Severity of disease changes following Engensis injections
Description
As assessed using the CMTNS v2 (Charcot Marie Tooth Neuropathy Score version The scores range from 0-36. The severity of disease shall be classified according to scores as mild (≤10), moderate (11 to 20), and severe (>20).
Time Frame
Day 0, 90, 180 and Day 270]
Title
Evaluation of patient's neurological disability
Description
As assessed using the FDS (functional disability scale). normal is 0 point, and if determined as bedridden, it is evaluated as 8 points.
Time Frame
Day 0, 90, 180 and Day 270
Title
Evaluation of the activity level of patients with peripheral neuropathy
Description
As assessed using the overall neuropathy limitation scale (ONLS) leg scale. It is scored from 0 to 7. The worst score, 7 points, is defined as restricted to wheelchair, or bed most of the day, unable to make any purposeful movements of the leg.
Time Frame
Day 0, 90, 180 and Day 270
Title
Evaluation of patient's walking ability
Description
This test measures the time required for a subject to walk 10m through the 10-Meter Walking Test (10MWT) v2.2.
Time Frame
Day 0, 90, 180 and Day 270
Title
Changes in fatty infiltration level of lower limb muscles
Description
Imaged via MRI.
Time Frame
Day 0 and Day 270
Title
Evaluation of the presence of a disorder in a neurotransmission pathway.
Description
As assessed using the Nerve Conduction Study (NCS) v2.0
Time Frame
Day 0 and Day 270
Title
Evaluation of the presence of hepatocyte growth factor in the body.
Description
As assessed using Anti-HGF Ab test
Time Frame
Day 0 and Day 270

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females ≥ 19 years of age and ≤ 65 years of age Patients with confirmed diagnosis of CMT1A by genetic testing Patients with mild to moderate severity assessed by Charcot Marie Tooth Neuropathy Score version 2 (CMTNS v2) with a score > 2 and ≤ 20 Individuals with lower limb muscle weakness with minimum dorsiflexion or more Individuals who voluntarily consented to participate in this study and signed the IRB approved informed consent form after listening to a description on the characteristics of this clinical study prior to all screening tests Individuals who can comply with the requirements in the clinical study In case of females of child bearing potential, those who test negative in a urine or serum pregnancy test at screening Individuals who practice medically approved contraceptive methods throughout the clinical study Exclusion Criteria: Patients with significant respiratory, circulatory, renal, gastrointestinal, hepatic, endocrine, hematologic, psychiatric disorders or other severe diseases, or alcohol or drug addiction who may develop safety issues or cause confusion in the interpretation of the clinical study results as determined by the principal investigator Patients with other neuromuscular diseases or neuropathy-inducing factors: Patients with chronic alcohol addiction, undergoing anticancer chemotherapy, or taking neurotoxic drugs Patients diagnosed with diabetes Patients diagnosed with inflammatory bowel disease Patients with a history of stroke or cerebral ischemic attack within 12 months prior to the screening date Patients with a history of coronary artery disease, such as myocardial infarction and unstable angina pectoris, within 12 months prior to the screening date Morbidly obese patients with body mass index (BMI) ≥ 37 Patients who underwent orthopedic surgery (corrective surgery for bone and ligament, artificial joint implantation, osteosynthesis, osteotomy, arthroscopic surgery) in the lower limbs within 6 months prior to the screening date Patients who may be affected by the muscle strength measurement test due to ankle contracture or surgery Patients with uncontrolled hypertension (if systolic blood pressure is ≥ 160 mmHg or diastolic blood pressure is ≥ 100 mmHg at screening) Patients or patient's immediate family members (parents, siblings, offspring) with a history of malignant tumors within the last 5 years prior to the screening date, excluding basal cell carcinoma or squamous cell carcinoma that occurs on the skin (if it is determined that there is no possibility of relapse after resection), or with a family history of familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC) Patients who have not completed a national cancer screening program applicable to their sex and age (if it cannot be confirmed that the relevant test was received at a national cancer screening center or a recognized screening center) However, if it is confirmed that the relevant test was received at a national cancer screening center or a recognized screening center during the screening period, and that the results were within normal range, the patients may participate in the clinical study. Common to males and females: If a patient is ≥ 50 years of age, the results of a colonoscopy within 5 years prior to the screening must be determined as being within normal range, and if adenomatous polyps are evident, the results of a colonoscopy within 1 year must be determined as being within normal range (inflammatory polyps or hyperplastic polyps are included in the normal range). If a patient is ≥ 40 years of age, the results of a gastroscopy within 2 years prior to the screening must be within normal range. If a patient is ≥ 54 years of age and has a 30 pack-year history of smoking or more, the results of a low-dose chest CT within 2 years prior to the screening must be within normal range. In case of liver cancer, carriers of hepatitis B or hepatitis C virus and patients with hepatic cirrhosis fall under the exclusion criteria. Females: For females ≥ 40 years of age, normal range findings must be confirmed in a mammogram within 2 years. For females ≥ 20 years of age, normal range findings must be confirmed in a Pap smear within 2 years. Patients diagnosed with active pulmonary tuberculosis Patients with HBV or HCV Patients who test positive in human immunodeficiency virus (HIV) antibody test Patients in an immunosuppressive state due to treatments such as immunosuppressants, chemotherapy, and radiotherapy Patients with a history of mental disease within 6 months prior to the screening date, which may interfere with participation in the study Patients who must take medications, that are known to have significant drug interactions within 14 days after the first administration of the investigational product or deemed unsuitable by the investigator's judgment Individuals who participated in another clinical study within 6 months before the time of screening Individuals who have shown significant adverse events such as hypersensitivity reactions to the investigational product Pregnant or breastfeeding females Other individuals determined ineligible by the principal investigator to participate in the clinical study due to other reasons including clinical laboratory test results
Facility Information:
Facility Name
Samsung Medical Center, Seoul National University Hospital
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

We'll reach out to this number within 24 hrs